paclitaxel has been researched along with Hand-Foot Syndrome in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (75.00) | 24.3611 |
| 2020's | 4 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ângela Ribeiro, M; de Araújo, LB; Dos Santos Pedroso, R; Duarte Silva Malvino, L; Moreira, TA; Nunes Filho, M; Pereira, PP | 1 |
| Eikenberg, JD; Engel, C; Quan, EY; Rush, PS | 1 |
| Lee, K; Reserva, J; Speiser, J; Zelman, B | 1 |
| Chiu, M; Cutler, L; Kim, G; Wang, H | 1 |
| Franco, L; McLellan, BN; Rzepecki, AK | 1 |
| Benekli, M; Berk, V; Buyukberber, S; Coskun, U; Demirci, U; Ozkan, M; Sevinc, A; Tonyali, O; Ucgul, E; Uncu, D; Yildiz, R | 1 |
| Ballardini, P; Borghi, A; Corazza, M; Minghetti, S; Virgili, A | 1 |
| Beckmann, M; Du Bois, A; Eidtmann, H; Heilmann, V; Hubalek, M; Huober, J; Jackisch, C; Loibl, S; Lück, HJ; Richter, B; Schrader, I; Schuster, T; Stähler, A; Stickeler, E; Thomssen, C; Untch, M; von Minckwitz, G; Wollschläger, K | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Andrade, F; Arai, RJ; Barroso-Sousa, R; Gagliato, DM; Hoff, PM; Leal, AI; Longo, E; Mano, MS; Petry, V; Piato, JR; Ricci, MD | 1 |
| Ajgal, Z; Alexandre, J; Boudou-Rouquette, P; Cessot, A; Chapuis, N; Emile, G; Fontenay, M; Goldwasser, F; Huillard, O; Tigaud, JM | 1 |
| Chekerov, R; Darvin, ME; Eucker, J; Fuss, H; Jung, S; Kühnhardt, D; Lademann, J; Lee, BN; Patzelt, A; Sehouli, J; Yu, RX | 1 |
| Camilleri, MJ; Repass, TS; Wetter, DA | 1 |
| Adams, BB; Housholder, AL | 1 |
| Chon, SY; Ivan, D; Rashid, RM; Richards, KN | 1 |
| Furuya, Y; Ishida, T; Masuda, N; Matsunami, N; Miyashita, M; Nagata, T; Nakayama, T; Noguchi, S; Nomura, M; Oba, K; Sakamoto, J; Taguchi, T; Wakita, K; Yamamoto, D; Yoshidome, K; Yoshino, H | 1 |
5 trial(s) available for paclitaxel and Hand-Foot Syndrome
| Article | Year |
|---|---|
Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neutropenia; Paclitaxel; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2013 |
Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Middle Aged; Paclitaxel; Quality of Life; Treatment Outcome | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2- locally advanced breast cancer.
Topics: Administration, Metronomic; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Doxorubicin; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Paclitaxel; Pneumonia; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab | 2015 |
Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Endpoint Determination; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Sample Size; Survival Analysis | 2013 |
11 other study(ies) available for paclitaxel and Hand-Foot Syndrome
| Article | Year |
|---|---|
Hand-foot syndrome and nail disorders secondary to treatment with paclitaxel: Is there a relationship with the presence of fungi?
Topics: Female; Hand-Foot Syndrome; Humans; Middle Aged; Nail Diseases; Onychomycosis; Paclitaxel; Prospective Studies; Trichophyton | 2022 |
Paclitaxel-induced dorsal hand-foot syndrome.
Topics: Aged; Drug-Related Side Effects and Adverse Reactions; Foot; Hand-Foot Syndrome; Humans; Male; Paclitaxel; Quality of Life | 2023 |
A paclitaxel-induced variant of hand-foot syndrome affecting dorsal surfaces.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Hand-Foot Syndrome; Humans; Middle Aged; Paclitaxel; Skin | 2021 |
Fixed erythrodysesthesia plaques at sites of intravenous docetaxel infusion: an unusual cutaneous reaction to chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hand-Foot Syndrome; Humans; Infusions, Intravenous; Paclitaxel | 2022 |
PATEO syndrome: periarticular thenar erythema with onycholysis.
Topics: Breast Neoplasms; Erythema; Female; Hand-Foot Syndrome; Humans; Joint Diseases; Middle Aged; Onycholysis; Paclitaxel; Syndrome | 2018 |
Hand-foot syndrome caused by docetaxel with no recurrence after switch to paclitaxel, a different taxane.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Docetaxel; Female; Hand-Foot Syndrome; Humans; Middle Aged; Paclitaxel; Secondary Prevention; Taxoids | 2014 |
Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Case-Control Studies; Doxorubicin; Female; Hand-Foot Syndrome; Hematologic Diseases; Humans; Leukocyte Count; Male; Middle Aged; Monocytes; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols; Retrospective Studies; Sarcoma; Stomatitis; Thymus Neoplasms; Young Adult | 2015 |
Influence of Chemotherapy on the Antioxidant Status of Human Skin.
Topics: Adult; Aged; Antineoplastic Agents; Antioxidants; Carotenoids; Docetaxel; Doxorubicin; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Skin; Taxoids | 2016 |
Toxic erythema of chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Hand-Foot Syndrome; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Small Cell Lung Carcinoma; Treatment Outcome | 2012 |
Chemotherapy-induced acral erythema sparing the palms.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Hand-Foot Syndrome; Humans; Middle Aged; Paclitaxel | 2012 |
Paclitaxel-induced acral erythema.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Female; Hand-Foot Syndrome; Humans; Paclitaxel | 2012 |